Media ReleasesImmutep

View All Immutep News

Immutep, Investor Update January 2019

Message from the CEO

Welcome to the first investor update of 2019 following a very meaningful and productive 2018 for Immutep. In this update we are pleased to give you a summary of the progress of our clinical programs, preclinical program and business development initiatives in the second half of last year and first few weeks of the New Year.

We are especially delighted with the progress of our partnerships in 2018. Immutep is now collaborating with five major pharma companies: Novartis, GSK, Merck & Co (MSD), Merck (Germany) and Pfizer. We are partnered with four of the world’s top 10 pharmaceutical companies, conferring strong validation of our technology, product candidates and R&D competencies.

To view Update please download PDF attached:
Download this document